

Maine Coon



LABGENVET (2021)

[Hypertrophic Cardiomyopathy](#)

Maine Coon (117 tests)

N/N	76.0%
M/N	21.4%
M/M	2.6%

[Pyruvate Kinase Deficiency](#)

(39 tests)

N/N	92.3%
M/N	7.7%
M/M	0.0%

[Polycystic Kidney Disease \(PKD\)](#)

(5 tests)

N/N	60.0%
M/N	40.0%
M/M	0.0%

[Anderson \(2022\)](#)

Hypertrophic Cardiomyopathy

Maine Coon (1840 tests)

N/N	91.9%
M/N	7.7%
M/M	0.4%

Pyruvate Kinase Deficiency

(1824 tests)

N/N	85.1%
M/N	14.3%
M/M	0.6%

Polycystic Kidney Disease (PKD)

(1835 tests)

N/N	99.8%
M/N	0.2%
M/M	0.0%

[Factor XII Deficiency \(Variant 2\)](#)

(259 tests)

N/N	79.2%
M/N	19.3%
M/M	1.5%

[Factor XII Deficiency \(Variant 1\)](#)

(1836 tests)

N/N	88.8%
M/N	10.9%
M/M	0.3%

[MDR1 Medication Sensitivity](#)

(1840 tests)

N/N	94.5%
M/N	5.4%
M/M	0.1%

[Mucopolysaccharidosis Type VI Modifier](#)

(1840 tests)

N/N	99.8%
M/N	0.2%
M/M	0.0%

[Progressive Retinal Atrophy \(Abyssinian\)](#)

(PRA-rdAc) (1840 tests)

N/N	99.9%
M/N	0.1%
M/M	0.0%

[Spinal Muscular Atrophy \(Maine Coon\)](#)

(1840 tests)

N/N	99.4%
M/N	0.6%
M/M	0.0%

[Cystinuria type B \(Variant 3\)](#)

(1840 tests)

N/N	99.7%
M/N	0.3%
M/M	0.0%

[Congenital Erythropoietic Porphyria \(c.140C>T\)](#)

(1840 tests)

N/N	99.9%
M/N	0.1%
M/M	0.0%